Top Medical Searches

Loxo signs lucrative cancer drug deal with Bayer, but shares fall

(Reuters) – Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany’s Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.

 Read more…

Be Sociable, Share!
November 14th, 2017 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us